氯霉素,56-75-7，生产厂家，价格-洛克化工网移动版

返回



基本信息

制备方法及用途

物化性质

安全信息

毒理性

MSDS

结构与计算化学

上游产品

下游产品

表征图谱

氯霉素

中文名称：: 氯霉素

中文别名：: 氯霉素;
D-苏式-(-)-N-[alpha-(羟基甲基)-beta-羟基-对硝基苯乙基]-2,2-二氯乙酰胺;
左旋-苏-1-(对硝基苯基)-2-二氯乙酰氨基-1,3-丙二醇;
D-(-)-苏-1-对硝基苯基-2-二氯乙酰胺基-1,3-丙二醇;
D-苏式-(-)-N-[α-(羟基甲基)-β-羟基-对硝基苯乙基]-2,2-二氯乙酰胺;
左旋霉素;
2,2-二氯-N-[2-羟基-1-(羟甲基)]-2-(4-硝基苯基)-乙基]乙酰胺

英文名称：: chloroamphenicol

英文别名：: chloramphenicol;
CAF;
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide;
Catilan;
Chlomin;
Ambofen;
Mychel;
Chloramphenicol;
chloroamphenicol;
2,2-dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]acetamide;
u-6062;
i337a;
D-(?)-threo-1-p-nitrophenyl-2-dichloracetamido-1,3-propanediol;
Enicol

CAS No.：: 56-75-7

分子式：: C₁₁H₁₂Cl₂N₂O₅

分子量：: 323.13

精确分子量：: 322.01200

PSA：: 115.38000

MDL：: MFCD00078159

EINECS：: 200-287-4

BRN：: 2225532

InChI：: InChI=1/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9?/m1/s13

危险品标志：: T

风险术语：: R45

安全术语：: S53;S45;

分子结构式：

SDS：: 查看

氯霉素毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :: AB6825000

CHEMICAL NAME :: Acetamide, 2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p- nitrophenethyl)-, D-(-)-threo-

CAS REGISTRY NUMBER :: 56-75-7

BEILSTEIN REFERENCE NO. :: 2225532

LAST UPDATED :: 199707

DATA ITEMS CITED :: 96

MOLECULAR FORMULA :: C11-H12-Cl2-N2-O5

MOLECULAR WEIGHT :: 323.15

WISWESSER LINE NOTATION :: WNR DYQY1QMVYGG

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - infant

DOSE/DURATION :: 440 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Gastrointestinal - other changes Nutritional and Gross Metabolic - body temperature decrease

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Behavioral - coma Vascular - shock Lungs, Thorax, or Respiration - cyanosis

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 250 mg/kg/10D

TOXIC EFFECTS :: Liver - other changes Blood - hemorrhage Blood - changes in bone marrow (not otherwise specified)

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - infant

DOSE/DURATION :: 30 mg/kg/3D-I

TOXIC EFFECTS :: Cardiac - cardiac output Vascular - BP lowering not characterized in autonomic section

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - infant

DOSE/DURATION :: 250 mg/kg/2D

TOXIC EFFECTS :: Vascular - change in plasma or blood volume

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Human - infant

DOSE/DURATION :: 200 mg/kg/4D-I

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Blood - eosinophilia Skin and Appendages - dermatitis, allergic (after systemic exposure)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1811 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5 gm/kg

TOXIC EFFECTS :: Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 171 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1100 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 110 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - other changes

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >300 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 150 mg/kg

TOXIC EFFECTS :: Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - other changes

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >101 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 117 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 560 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 60 mg/kg/60D-I

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 17416 mg/kg/4W-I

TOXIC EFFECTS :: Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 33600 mg/kg/14D-C

TOXIC EFFECTS :: Liver - other changes Liver - changes in liver weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 960 mg/kg/4D-I

TOXIC EFFECTS :: Blood - changes in other cell count (unspecified) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - dehydrogenases

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2800 mg/kg/2W-I

TOXIC EFFECTS :: Behavioral - food intake (animal) Nutritional and Gross Metabolic - other changes Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 6400 mg/kg/3W-I

TOXIC EFFECTS :: Behavioral - food intake (animal) Kidney, Ureter, Bladder - proteinuria

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 2100 mg/kg/2W-C

TOXIC EFFECTS :: Nutritional and Gross Metabolic - other changes Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 300 mg/kg/60W-I

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Blood - changes in bone marrow (not otherwise specified) Blood - leukemia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2500 mg/kg/5W-I

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 1680 mg/kg/6W-I

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Blood - aplastic anemia Blood - leukemia

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 434 mg/kg/W-C

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Blood - aplastic anemia Blood - leukemia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 23 gm/kg

SEX/DURATION :: female 1-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - homeostasis

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2500 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2500 mg/kg

SEX/DURATION :: female 11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2 gm/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - body wall

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 250 mg/kg

SEX/DURATION :: female 3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2400 mg/kg

SEX/DURATION :: female 12-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 3500 mg/kg

SEX/DURATION :: female 6-10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 3500 mg/kg

SEX/DURATION :: female 6-10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 2 gm/kg

SEX/DURATION :: female 10-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Effects on Embryo or Fetus - other effects to embryo

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 5500 mg/kg

SEX/DURATION :: female 5-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 7 gm/kg

SEX/DURATION :: female 6-12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 6 gm/kg

SEX/DURATION :: female 8-10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 175 mg/kg

SEX/DURATION :: female 15-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2 gm/kg

SEX/DURATION :: female 12-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 4 gm/kg

SEX/DURATION :: female 8-11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 4 gm/kg

SEX/DURATION :: female 6-9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2700 mg/kg

SEX/DURATION :: female 11-19 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - abortion Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2700 mg/kg

SEX/DURATION :: female 2-10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :: Sister chromatid exchange

TEST SYSTEM :: Mammal - cattle Lymphocyte

DOSE/DURATION :: 5 mg/L

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 319,11,1993 *** REVIEWS *** IARC Cancer Review:Human Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 10,85,1976 IARC Cancer Review:Human Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,169,1990 IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 10,85,1976 IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,169,1990 IARC Cancer Review:Group 2A IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,169,1990 TOXICOLOGY REVIEW PLMJAP Pahlavi Medical Journal. (Shiraz, Iran) V.1-9, 1970-78. Volume(issue)/page/year: 6,160,1975 TOXICOLOGY REVIEW CLANA4 Clinical Anesthesia. (Philadelphia, PA 19103) V.1-11, 1963-76. Volume(issue)/page/year: 10(Pt 1),283,1973 TOXICOLOGY REVIEW PCNAA8 Pediatric Clinics of North America. (W.B. Saunders Co., W. Washington Sq., Philadelphia, PA 19105) V.1- 1954- Volume(issue)/page/year: 8,413,1961 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-RUSSIA:STEL 1 mg/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84396 No. of Facilities: 165 (estimated) No. of Industries: 1 No. of Occupations: 6 No. of Employees: 11365 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84396 No. of Facilities: 2358 (estimated) No. of Industries: 3 No. of Occupations: 19 No. of Employees: 35571 (estimated) No. of Female Employees: 23544 (estimated)

氯霉素 MSDS

模块 1. 化学品
  1.1 产品标识符
    : 氯霉素
    产品名称
  1.2 鉴别的其他方法
    D-(−)-threo-2-Dichloroacetamido-1-(4-nitrophenyl)-1,3-propanediol
    Chloromycetin®
    D-(−)-threo-2,2-Dichloro-N-[β-hydroxy-α-(hydroxymethyl)-β-(4-nitrophenyl)ethyl]acetamide
    D-threo-2,2-Dichloro-N-[β-hydroxy-α-(hydroxymethyl)-4-nitrophenethyl]acetamide
  1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
    仅用于研发。不作为药品、家庭或其它用途。

模块 2. 危险性概述
  2.1 GHS-分类
    急性毒性, 经口 (类别 5)
    致癌性 (类别 1B)
  2.2 GHS 标记要素，包括预防性的陈述
    象形图
    警示词        危险
    危险申明
    H303        吞咽可能有害。
    H350        可能致癌。
    警告申明
    预防措施
    P201        在使用前获取特别指示。
    P202        在读懂所有安全防范措施之前切勿操作。
    P280        戴防护手套/穿防护服/戴护目镜/戴面罩.
    事故响应
    P308 + P313        如接触到或有疑虑：求医/ 就诊。
    安全储存
    P405        存放处须加锁。
    废弃处置
    P501        将内容物/ 容器处理到得到批准的废物处理厂。
    只限于专业使用者。
  2.3 其它危害物 - 无

模块 3. 成分/组成信息
  3.1 物质
    : D-(−)-threo-2-Dichloroacetamido-1-(4-nitrophenyl)-1,3-propanediol
    别名
    Chloromycetin®
    D-(−)-threo-2,2-Dichloro-N-[β-hydroxy-α-(hydroxymethyl)-β-(4-
    nitrophenyl)ethyl]acetamide
    D-threo-2,2-Dichloro-N-[β-hydroxy-α-(hydroxymethyl)-4-
    nitrophenethyl]acetamide
    : C11H12Cl2N2O5
    分子式
    : 323.13 g/mol
    分子量
    组分        浓度或浓度范围
    Chloramphenicol
    <=100%
    化学文摘登记号(CAS        56-75-7
    No.)        200-287-4
    EC-编号

模块 4. 急救措施
  4.1 必要的急救措施描述
    一般的建议
    请教医生。向到现场的医生出示此安全技术说明书。
    吸入
    如果吸入,请将患者移到新鲜空气处。如呼吸停止,进行人工呼吸。请教医生。
    皮肤接触
    用肥皂和大量的水冲洗。请教医生。
    眼睛接触
    用水冲洗眼睛作为预防措施。
    食入
    切勿给失去知觉者通过口喂任何东西。用水漱口。请教医生。
  4.2 主要症状和影响，急性和迟发效应
    恶心, 头痛, 呕吐
  4.3 及时的医疗处理和所需的特殊处理的说明和指示
    无数据资料

模块 5. 消防措施
  5.1 灭火介质
    灭火方法及灭火剂
    用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
  5.2 源于此物质或混合物的特别的危害
    碳氧化物, 氮氧化物, 氯化氢气体
  5.3 给消防员的建议
    如必要的话,戴自给式呼吸器去救火。
  5.4 进一步信息
    无数据资料

模块 6. 泄露应急处理
  6.1 作业人员防护措施、防护装备和应急处置程序
    使用个人防护用品。避免粉尘生成。避免吸入蒸气、烟雾或气体。保证充分的通风。
    人员疏散到安全区域。避免吸入粉尘。
  6.2 环境保护措施
    如能确保安全，可采取措施防止进一步的泄漏或溢出。不要让产品进入下水道。
  6.3 泄漏化学品的收容、清除方法及所使用的处置材料
    收集和处置时不要产生粉尘。扫掉和铲掉。放入合适的封闭的容器中待处理。
  6.4 参考其他部分
    丢弃处理请参阅第13节。

模块 7. 操作处置与储存
  7.1 安全操作的注意事项
    避免曝露：使用前需要获得专门的指导。避免形成粉尘和气溶胶。
    在有粉尘生成的地方,提供合适的排风设备。
  7.2 安全储存的条件,包括任何不兼容性
    贮存在阴凉处。使容器保持密闭，储存在干燥通风处。
    对光线敏感
  7.3 特定用途
    无数据资料

模块 8. 接触控制和个体防护
  8.1 容许浓度
    最高容许浓度
  8.2 暴露控制
    适当的技术控制
    根据良好的工业卫生和安全规范进行操作。休息前和工作结束时洗手。
    个体防护设备
    眼/面保护
    带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟)
    检测与批准的设备防护眼部。
    皮肤保护
    戴手套取手套在使用前必须受检查。
    请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
    使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
    所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
    完全接触
    物料: 丁腈橡胶
    最小的层厚度 0.11 mm
    溶剂渗透时间: 480 min
    测试过的物质Dermatril® (KCL 740 / Z677272, 规格 M)
    飞溅保护
    物料: 丁腈橡胶
    最小的层厚度 0.11 mm
    溶剂渗透时间: 480 min
    测试过的物质Dermatril® (KCL 740 / Z677272, 规格 M)
,     测试方法 EN374
    如果以溶剂形式应用或与其它物质混合应用，或在不同于EN
    374规定的条件下应用，请与EC批准的手套的供应商联系。
    这个推荐只是建议性的,并且务必让熟悉我们客户计划使用的特定情况的工业卫生学专家评估确认才可.
    这不应该解释为在提供对任何特定使用情况方法的批准.
    身体保护
    防渗透的衣服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
    呼吸系统防护
    如危险性评测显示需要使用空气净化的防毒面具，请使用全面罩式多功能微粒防毒面具N100型（US
    ）或P3型（EN
    143）防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式，则使用全面罩式送风防毒
    面具。呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。

模块 9. 理化特性
  9.1 基本的理化特性的信息
    a) 外观与性状
    形状: 结晶
    颜色: 淡黄
    b) 气味
    无数据资料
    c) 气味阈值
    无数据资料
    d) pH值
    无数据资料
    e) 熔点/凝固点
    熔点/凝固点: 148 - 150 °C - lit.
    f) 沸点、初沸点和沸程
    无数据资料
    g) 闪点
    无数据资料
    h) 蒸发速率
    无数据资料
    i) 易燃性(固体,气体)
    无数据资料
    j) 高的/低的燃烧性或爆炸性限度无数据资料
    k) 蒸气压
    无数据资料
    l) 蒸汽密度
    无数据资料
    m) 密度/相对密度
    无数据资料
    n) 水溶性
    实际上不溶
    o) n-辛醇/水分配系数
    无数据资料
    p) 自燃温度
    无数据资料
    q) 分解温度
    无数据资料
    r) 粘度
    无数据资料

模块 10. 稳定性和反应活性
  10.1 反应性
    无数据资料
  10.2 稳定性
    无数据资料
  10.3 危险反应
    无数据资料
  10.4 应避免的条件
    无数据资料
  10.5 不相容的物质
    酸, 酰基氯, 酸酐, 氧化剂
  10.6 危险的分解产物
    其它分解产物 - 无数据资料

模块 11. 毒理学资料
  11.1 毒理学影响的信息
    急性毒性
    半数致死剂量 (LD50) 经口 - 大鼠 - 2,500 mg/kg
    半数致死剂量 (LD50) 腹膜内的 - 大鼠 - 1,811 mg/kg
    半数致死剂量 (LD50) 腹膜内的 - 小鼠 - 1,100 mg/kg
    皮肤刺激或腐蚀
    无数据资料
    眼睛刺激或腐蚀
    无数据资料
    呼吸道或皮肤过敏
    长期或反复接触导致个别人过敏反应
    生殖细胞致突变性
    实验室测试表明由诱变效应
    细胞突变性-体外试验 - 大鼠 - 肝
    DNA损伤
    细胞突变性-体内试验 - 小鼠 - 腹膜内的
    细胞发生分析
    致癌性
    该产品是或包含被IARC, ACGIH, EPA, 和 NTP 列为可能是致癌物的组分
    可能的人类致癌物
    IARC:
    2A - 第2A组：或许对人类致癌 (Chloramphenicol)
    生殖毒性
    无数据资料
    特异性靶器官系统毒性（一次接触）
    无数据资料
    特异性靶器官系统毒性（反复接触）
    无数据资料
    吸入危险
    无数据资料
    潜在的健康影响
    吸入        吸入可能有害。可能引起呼吸道刺激。
    摄入        如服入是有害的。
    皮肤        通过皮肤吸收可能有害。可能引起皮肤刺激。
    眼睛        可能引起眼睛刺激。
    接触后的征兆和症状
    恶心, 头痛, 呕吐
    附加说明
    化学物质毒性作用登记: AB6825000

模块 12. 生态学资料
  12.1 生态毒性
    对水蚤和其他水生无脊        半数效应浓度（EC50） - 大型蚤 (水蚤) - 345 mg/l - 48 h
    椎动物的毒性
  12.2 持久性和降解性
    无数据资料
  12.3 潜在的生物累积性
    无数据资料
  12.4 土壤中的迁移性
    无数据资料
  12.5 PBT 和 vPvB的结果评价
    无数据资料
  12.6 其它不良影响
    无数据资料

模块 13. 废弃处置
  13.1 废物处理方法
    产品
    将剩余的和不可回收的溶液交给有许可证的公司处理。
    与易燃溶剂相溶或者相混合，在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧
    受污染的容器和包装
    按未用产品处置。

模块 14. 运输信息
  14.1 联合国危险货物编号
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.2 联合国运输名称
    欧洲陆运危规: 非危险货物
    国际海运危规: 非危险货物
    国际空运危规: 非危险货物
  14.3 运输危险类别
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.4 包裹组
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.5 环境危险
    欧洲陆运危规: 否        国际海运危规        国际空运危规: 否
    海洋污染物（是/否）: 否
  14.6 对使用者的特别提醒
    无数据资料

模块 15 - 法规信息
N/A

模块16 - 其他信息
N/A